Marché mondial des infections fongiques – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché des infections fongiques

Le marché mondial des infections fongiques devrait connaître une croissance significative au cours de la période de prévision. Les symptômes des infections fongiques dépendent du type d'infection fongique. Les symptômes courants comprennent des démangeaisons et des changements cutanés, notamment des rougeurs et éventuellement une desquamation ou des craquelures de la peau. Ce type d'infection peut être traité avec des médicaments antifongiques. Ces médicaments peuvent tuer directement les champignons ou les empêcher de prospérer et de se développer. Les médicaments antifongiques sont disponibles sous plusieurs formes, notamment sous forme de poudre, de pilules, de sprays, de shampooings et de crèmes ou de pommades.

Data Bridge Market Research analyse le taux de croissance du marché mondial des infections fongiques au cours de la période de prévision 2022-2029. Le TCAC attendu du marché mondial des médicaments contre les infections à Candida tend à être d'environ 4,00 % au cours de la période de prévision mentionnée. Le marché était évalué à 14,42 milliards USD en 2021 et devrait atteindre 19,73 milliards USD d'ici 2029. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des infections fongiques

Market Definition

Fungal infections are common in the natural world. Infection occurs when an invading fungus enters the body, and the immune system becomes too weak to handle the abnormalities. Fungal infections can occur anywhere on the body. The most common fungal infections are ringworm, jock itch, athlete's foot, and yeast. This disease prevalence is rising, and important diagnostic procedures and treatments will boost the market's growth.

Global Fungal Infections Market Dynamics

Drivers

• Increased Demand for Diagnostic Tests

Diagnostic tests, such as medical imaging, including C.T. scans and X-rays, are usually performed to detect pneumocystis pneumonia. In addition, biopsy involves extracting a small part of the infected tissue and is examined under the microscope for the presence of a specific fungus. It is generally performed for the diagnosis of aspergillosis, pneumocytosis pneumonia, and sporotrichosis. Thus, it acts as a major driver in market growth.

• The rise in Cryptococcal Meningitis

As per the Centers for Disease Control and Prevention, an estimated 220,000 new cases of cryptococcal meningitis occur globally every year, and around 181,000 deaths occur because of cryptococcal meningitis. Cryptococcal meningitis is a deadly brain infection caused by the soil-dwelling fungus Cryptococcus.

Opportunities

• Rising Existence of Several Fungal Infections

Several fungal infections are helping in boosting the growth of the market. Pneumocystis pneumonia is the most severe and commonly occurring fungal infection that is caused by the fungus Pneumocystis jirovecii. It is most widespread in individuals with weakened immune systems, such as those with AIDS. Other than these, Dermatophytes and Candidiasis are two other types of commonly occurring fungal infections. Candidiasis majorly affects soft, moist areas or skin around the nails. For instance, vaginal yeast infection in women and baby diaper rash occurs because of candidiasis. All these factors are also contributing to the growth of the market.  

• Increasing Demand for Retail Pharmacies

The rise in the number of drugs used for the global fungal infections market delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for market growth. In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel unable to perform these treatments could reduce the growth of the global fungal infections market over a forecast period.

• Unavailability of Appropriate Treatments

To treat conditions that are rare, many times, all treatments are not available, especially in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in hospitals and clinics. Thus, it hampers market growth.

This global fungal infections market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global fungal infections market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Fungal Infections Market

Even though in the COVID-19 pandemic, the shift was on eliminating the infection and vaccine production, the fungal infections were hit, and the link between the two was established. Currently, fungal infection cases are increasing among people because of the ideal environment in COVID-19 patients, low oxygen, acidic medium (diabetic ketoacidosis and others), high iron levels, high glucose, and suppressed immune system, along with other comorbidities. Government authorities are spreading more and more awareness for the early detection and management of fungal infections in COVID-19 patients. For instance, guidelines have been released by the Indian Council of Medical Research (ICMR), i.e., Do's and Don'ts for the COVID – 19 patients.

Global Fungal Infections Market Scope

The global fungal infections market is segmented on the basis of types, drugs, treatment, dosage form, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Aspergillosis
• Blastomycosis
• Candidiasis
• Candida auris
• Coccidioidomycosis
• Cryptococcus gattii infection
• Fungal Eyes Infection
• Fungal Nail Infection
• Histoplasmosis
• Ringworm
• Others 

Drugs

• Corticosteroids
• Corticosteroid-Sparing Agents
• Immunosuppressive
• Immunomodulator
• Antifungals
• Others

Treatment

• Antifungal
• Others

Dosage Form

• Creams
•  Gels
•  Ointment
• Solution
• Lotions
• Others

Route of Administration

• Oral
• Parenteral
• Topical
• Vaginal
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Fungal Infections Market Regional Analysis/Insights

The global fungal infections market is analysed and market size insights and trends are provided by drugs, treatment, dosage form, route of administration, end-user, distribution channel as referenced above.

The major countries covered in the global fungal infections market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market due to the highest number of patients diagnosed with a skin infections and increased R&D and healthcare expenditure.

Asia-Pacific is considered to have the most lucrative period due to increased campaign programs for skincare products, favorable environmental conditions for manufacturing, and number of generic drugs. 

La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché mondiales des infections fongiques

Le paysage concurrentiel du marché mondial des infections fongiques fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial des infections fongiques.

Les principaux acteurs opérant sur le marché mondial des infections fongiques comprennent :

• F. Hoffmann-La Roche SA (Suisse)

• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GSK plc (Royaume-Uni)
• Novartis SA (Suisse)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Merck & Co., Inc. (États-Unis)
• Société Bristol-Myers Squibb (États-Unis)
• Lilly (États-Unis)
• Amgen Inc. (États-Unis)

SKU-55532